TL1A Inhibitor Pipeline in IBD — PatSnap Eureka
TL1A Inhibitor Pipeline in IBD: Tulisokibart & TNFSF15 Targeting
TL1A (TNFSF15) has emerged as a mechanistically distinct target driving both intestinal inflammation and fibrosis in IBD — with up to 45% of initial biologic responders losing response over time under current regimens. Explore the full patent and clinical landscape of anti-TL1A programs including tulisokibart, genotype-guided selection, and TL1A+IL-23 combination strategies.
IP Activity by Assignee — TL1A Inhibitor Space
Prometheus Biosciences/Roche leads retrieved patent volume across antibody composition, CDx, and combination methods.
The TL1A-DR3 Axis: Inflammation and Fibrosis in IBD
TL1A (TNFSF15 gene product; UniProtKB: O95150) and its cognate receptor death receptor 3 (DR3) form the central therapeutic axis in this dataset. TL1A is consistently described as upregulated in inflamed IBD tissue, with expression levels correlating with disease severity. Genentech/Roche patent filings note that "TL1A has been found to be upregulated in IBD tissue specimens, with level of expression corresponding to the severity of disease" and that "variants in TNFSF15 have been linked to the pathogenesis of several autoimmune diseases, including psoriasis, rheumatoid arthritis, and multiple sclerosis."
DR3 is a TNF-family death receptor predominantly expressed on T cells, natural killer (NK) cells, NK-T cells, innate lymphoid cells (ILCs), fibroblasts, and epithelial cells. Prometheus Biosciences filings describe how "TL1A sends signals through death receptor 3 (DR3) and powerfully drives Th1, Th2, Th9, and Th17 responses" and is "induced in antigen-presenting cells by toll-like receptor (TLR) ligands and FcR crosslinking, and in T cells by T cell receptor (TCR) stimulation." This broad immune activation profile distinguishes TL1A from other IBD targets such as NIH-studied anti-TNFα or integrin-blocking pathways.
A critical biological feature is the dual role of the TL1A-DR3 axis in both inflammation and intestinal fibrosis. Pfizer patent filings note that "TL1A expression is associated with fibrostenotic Crohn's disease and can directly activate fibroblasts to stimulate inflammation-associated fibrosis." Downstream signaling mediators include IFN-gamma, IL-17, IL-5, IL-13, IL-22, GM-CSF, OX40L, TGFβ1, IGF1, CTGF, and IL-31Ra. You can explore the full PatSnap patent landscape analytics platform for deeper competitive intelligence on this pathway.
Four Distinct Approaches to TL1A-DR3 Axis Inhibition
Retrieved patent results reveal four mechanistically distinct modalities targeting the TL1A pathway in IBD, spanning direct ligand blockade, receptor inhibition, precision patient selection, and combination regimens.
Anti-TL1A Monoclonal Antibodies (Direct Ligand Blockade)
This modality dominates the retrieved dataset. Pfizer's tulisokibart (PF-06480101) is covered by a family of method-of-use patents describing an induction/maintenance dosing regimen spanning at least 12 weeks induction with multiple doses, followed by maintenance doses separated by at least 2 weeks — explicitly covering both CD and UC across US, WO, CA, MX, JP, and CN jurisdictions. Prometheus Biosciences' humanized anti-TL1A antibody (A219) is described across an extensive patent family covering antibody compositions with "high sequence homology to human germline frameworks" while maintaining "high binding affinity, high-level expression in bacterial and mammalian culture, and fewer sequence liabilities such as deamidation sites." Genentech filings (2024–2026) focus on non-responder risk stratification, signaling a companion diagnostic dimension. Explore the PatSnap life sciences IP platform for full antibody composition claim analysis.
Pfizer · Prometheus/Roche · GenentechAnti-DR3 Inhibitors (Receptor Blockade)
Cedars-Sinai Medical Center's foundational IP family explicitly claims DR3 inhibitors — including anti-DR3 antibodies — as co-equal therapeutic targets alongside TL1A inhibitors. The rationale is mechanistically equivalent: blocking the receptor prevents TL1A-DR3 signaling irrespective of ligand levels. Retrieved filings describe "one or more inhibitors of TL1A, DR3 and IL31RA signaling function" as a combined composition strategy. Preclinical data includes murine DSS colitis and T-cell transfer colitis models demonstrating reversal of collagen deposition. Cedars-Sinai's earliest filings date to 2014 WO/CA/AU priority, establishing the foundational scientific rationale for the entire field.
Cedars-Sinai Medical Center · Preclinical StageGenotype-Guided TL1A Inhibitor Administration (CDx)
A structurally distinct modality developed by Prometheus Biosciences across a large patent family. These filings cover patient stratification based on TNFSF15-linked genotypes, TL1A isoform ratios, and multi-gene predictive models. Retrieved results describe genotype-based prediction of positive therapeutic response "with an accuracy of at least about 50%–100%." Companion diagnostic models based on TL1A isoform ratios serve as proxy markers for elevated TL1A activity. Multiple Prometheus AU filings (2023, 2024) explicitly depict the study schema for induction period for the Phase 2 clinical trial for A219 in UC, indicating an active clinical program has informed the IP filings. This precision medicine approach may enable better Phase 2/3 trial success rates and eventual CDx label language per FDA companion diagnostic frameworks.
Prometheus/Roche · US, WO, AU, CA ActiveTL1A Inhibitor + IL-23 Inhibitor Combination Regimen
The most prominent combination signal in this dataset. Prometheus Biosciences describes co-administration of a TL1A inhibitor and an IL-23 inhibitor "contemporaneously for the duration of treatment or contemporaneously during an induction phase of treatment followed by maintenance of response with the TL1A inhibitor alone or IL23 inhibitor alone." Retrieved filings specify intravenous induction doses of "approximately 400–600 mg TL1A inhibitor" followed by maintenance doses of "approximately 175–300 mg every 2 or 4 weeks." The mechanistic complementarity is that TL1A drives broad T cell effector programs and ILC responses while IL-23 governs pathogenic Th17 differentiation and maintenance. Approved IL-23 inhibitors listed as potential partners include ustekinumab, guselkumab, risankizumab, brazikumab, and mirikizumab.
Prometheus/Roche · WO 2023 · US 2025TL1A Pipeline: Key Data Signals from Patent Analysis
Visualisations derived from patent literature retrieved via PatSnap Eureka. All values reflect retrieved dataset signals only — not a comprehensive field survey.
TL1A Inhibitor Modality Coverage by IP Layer
Prometheus/Roche holds the broadest multi-layer IP position spanning antibody composition, CDx, combination methods, and patient selection — creating a multi-layered patent fortress across key jurisdictions.
TL1A Inhibitor IP Filing Timeline by Key Program
Filing activity spans 2014–2026, with Cedars-Sinai establishing foundational IP and Prometheus/Roche driving the most recent broadening of claims across jurisdictions.
Key IP Holders in the TL1A Inhibitor Space
Innovation in this dataset is overwhelmingly patent-driven. The following organizations account for dominant IP activity across the TL1A-DR3 axis.
| Assignee | Program / Asset | Key IP Focus | Active Jurisdictions | Filing Range |
|---|---|---|---|---|
| Prometheus Biosciences / Roche | A219 / tulisokibart | Antibody Composition Genotype CDx TL1A+IL-23 Combo | US, WO, CN, JP, AU, BR, CA, NZ, CO, ID, MX, TW | 2020–2026 |
| Pfizer Inc. | Tulisokibart (PF-06480101) | Method of Use Induction/Maintenance Dosing | US, WO, CA, MX, JP, CN | 2021–2023 |
| Genentech / F. Hoffmann-La Roche AG | Anti-TL1A program (post-Prometheus acquisition) | Non-responder Risk Stratification IBD Treatment Methods | US, AU, TW, WO | 2024–2026 |
| Cedars-Sinai Medical Center | Foundational TL1A-DR3 IP | Fibrosis Reversal DR3 Inhibition IL-31Ra | US (active 2016, 2020 grants) | 2014–2020 |
Monitor TL1A patent filings in real time
PatSnap Eureka tracks new filings, legal status changes, and claim amendments across all assignees and jurisdictions.
Strategic Implications for TL1A Program Development
Key strategic signals derived from the retrieved patent dataset. All implications are traceable to specific filings and should inform IP strategy, clinical trial design, and competitive positioning.
Multi-Layered Patent Fortress at Method-of-Use & Patient-Selection Layers
IP landscape is heavily concentrated at the method-of-use and patient-selection layers. Prometheus Biosciences/Roche holds a dominant position spanning antibody composition, genotype-based patient selection, isoform-ratio CDx, and TL1A+IL-23 combination methods — creating a multi-layered patent fortress that competitors entering this space must design around, particularly in jurisdictions where these filings remain active (US, AU, WO, CN, JP, BR).
Fibrosis as Differentiated Clinical Value Proposition vs. Existing IBD Biologics
Retrieved results consistently highlight the dual anti-inflammatory and anti-fibrotic mechanism of TL1A-DR3 blockade, particularly relevant for fibrostenotic CD patients poorly served by current anti-TNFα, anti-integrin, and anti-IL-23 agents. This differentiation should inform clinical trial endpoint selection — for example, bowel wall thickness by MRI and histologic fibrosis scoring — and regulatory strategy. The EMA and FDA have increasingly recognized fibrosis endpoints in IBD trials.
From Patent Filings to Clinical Program Evidence
Retrieved results contain several signals suggesting active clinical translation, though direct clinical trial outcome data is not present in the retrieved text. Multiple Prometheus Biosciences patent filings retrieved from AU (2023, 2024) explicitly depict "the study schema for induction period for the phase 2 clinical trial for A219 in UC" and "open-label extension period" in their figures, indicating an active clinical program has informed the IP filings.
Pfizer filings describe a specific clinical regimen structure — multiple induction doses over at least 12 weeks followed by biweekly or monthly maintenance doses — consistent with IND-enabling and Phase 2/3 design considerations. The specificity of these dosing parameters in patent claims typically reflects data from human studies informing IP protection. The ClinicalTrials.gov registry and PatSnap customer case studies demonstrate how IP filing specificity correlates with clinical stage advancement.
Genentech's 2024–2026 filings describe "determining the risk of a patient being non-responsive to a therapeutic dose of an anti-TL1A antibody," suggesting clinical data on response heterogeneity is informing IP strategy. No retrieved result explicitly reports Phase 2 or Phase 3 efficacy endpoints or regulatory submission status. For comprehensive clinical pipeline monitoring, the PatSnap analytics platform integrates patent and clinical trial data in a unified view.
TL1A Inhibitors in IBD — Key Questions Answered
TL1A (TNFSF15 gene product) is a TNF superfamily cytokine that signals through its receptor death receptor 3 (DR3). It is upregulated in inflamed IBD tissue, with expression levels correlating with disease severity. The TL1A-DR3 axis drives Th1, Th2, Th9, and Th17 T helper responses as well as ILC2 and ILC3 effector functions, and plays a dual role in both intestinal inflammation and fibrosis — making it a compelling mechanistically distinct target for IBD.
Tulisokibart (PF-06480101) is an anti-TL1A monoclonal antibody being developed by Pfizer Inc. It is covered by a family of method-of-use patents describing an induction/maintenance dosing regimen for IBD. The induction phase spans at least 12 weeks with multiple induction doses, followed by a maintenance phase with doses separated by at least 2 weeks. The filing explicitly covers both Crohn's disease and ulcerative colitis. Prometheus Biosciences also references A219/tulisokibart in the context of a Phase 2 UC trial schema.
Prometheus Biosciences has developed a patient stratification framework based on the presence of TNFSF15-linked genotypes, TL1A isoform ratios, and multi-gene predictive models. Retrieved results describe genotype-based prediction of positive therapeutic response with an accuracy of at least about 50%–100%. Companion diagnostic models based on TL1A isoform ratios serve as proxy markers for elevated TL1A activity, enabling selection of patients most likely to respond to anti-TL1A therapy.
The most prominent combination signal is TL1A inhibitor plus IL-23 inhibitor, described by Prometheus Biosciences as co-administration contemporaneously during an induction phase followed by maintenance with either agent alone. Approved IL-23 inhibitors listed as potential partners include ustekinumab, guselkumab, risankizumab, brazikumab, and mirikizumab. Cedars-Sinai Medical Center has also described triple-pathway inhibition — TL1A, DR3, and IL-31Ra — as a compositional strategy for IBD and its fibrotic complications.
TL1A expression is associated with fibrostenotic Crohn's disease and can directly activate fibroblasts to stimulate inflammation-associated fibrosis. Cedars-Sinai Medical Center filings from as early as 2014 established the foundational IP linking TL1A-DR3 inhibition to reversal of established colonic fibrosis in murine models. This dual anti-inflammatory and anti-fibrotic mechanism differentiates TL1A inhibitors from current anti-TNFα, anti-integrin, and anti-IL-23 agents, which do not address the fibrotic component of fibrostenotic CD.
The dominant IP holders in this dataset are Prometheus Biosciences (acquired by Roche/Genentech), Pfizer Inc., Genentech/F. Hoffmann-La Roche AG, and Cedars-Sinai Medical Center. Prometheus Biosciences is the most active assignee by volume, spanning antibody compositions, patient selection genotyping, isoform-ratio CDx models, and TL1A+IL-23 combination methods across jurisdictions including US, WO, CN, JP, AU, BR, and CA. Cedars-Sinai holds the foundational IP with the earliest TL1A-DR3 filings from 2014.
Still have questions about TL1A inhibitors or the IBD patent landscape? Let PatSnap Eureka answer them.
Ask PatSnap Eureka About TL1AAccelerate Your TL1A and IBD Drug Discovery Intelligence
Join 18,000+ innovators already using PatSnap Eureka to map patent landscapes, identify combination opportunities, and track competitive programs in real time.
References
- Methods for treatment of inflammatory bowel disease with an Anti-TL1a antibody — F. Hoffmann-La Roche AG, 2025, WO [Patent]
- Methods for treatment of inflammatory bowel disease with an Anti-TL1a antibody — Genentech, Inc., 2025, US [Patent]
- Methods of treating inflammatory diseases with combination of TL1a inhibitors and IL23 inhibitors — Prometheus Biosciences, Inc., 2023, WO [Patent]
- Methods of treating inflammatory bowel disease with TL1a antibodies — Pfizer Inc., 2021, WO [Patent]
- Method of treatment of inflammatory bowel disease using Anti-TL1a antibodies — Pfizer Inc., 2023, US [Patent]
- Treating fibrosis and inflammation by inhibiting TL1a — Cedars-Sinai Medical Center, 2014, WO [Patent]
- Mitigation and reversal of fibrosis and inflammation by inhibition of TL1a function and related signaling pathways — Cedars-Sinai Medical Center, 2020, US [Patent]
- Compositions comprising humanized antibodies to TNF-like ligand 1a (TL1a) and uses thereof — Prometheus Biosciences, Inc., 2022, WO [Patent]
- Anti-TL1a antibody therapeutic methods — Genentech, Inc., 2025, AU [Patent]
- Anti-TL1a antibody therapeutic methods — Genentech, Inc., 2026, US [Patent]
- Methods, systems, and kits for treatment of inflammatory diseases targeting TL1a — Prometheus Biosciences, Inc., 2026, US [Patent]
- Methods, systems, and kits for treatment of inflammatory diseases by targeting TL1a — Prometheus Biosciences, Inc., 2024, WO [Patent]
- Methods of treating inflammatory diseases with combination of TL1a inhibitors and IL23 inhibitors — Prometheus Biosciences, Inc., 2025, US [Patent]
- Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha — Janssen Biotech, Inc., 2022, WO [Patent]
- Distinct effects of IFN-gamma and IL-17 on TL1a modulated inflammation and fibrosis — Cedars-Sinai Medical Center, 2014, WO [Patent]
- UniProtKB — O95150 (TNFSF15 / TL1A protein entry)
- National Institutes of Health (NIH) — IBD and cytokine biology research resources
- ClinicalTrials.gov — IBD clinical trial registry
- U.S. Food and Drug Administration (FDA) — Companion diagnostic framework guidance
- European Medicines Agency (EMA) — IBD regulatory guidance
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only — it should not be interpreted as a comprehensive view of the full field, clinical pipeline, or regulatory landscape.
PatSnap Eureka searches patents and research to answer instantly.